TargetBeta
CD2
CD2 molecule · also SRBC · CD molecules
3 programs in company-led studies act on CD2, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| siplizumabrule | ITB-Med | phase 2 | 172 running | – | ChEMBL |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 33 running | CD19, CD3E | the company's pipeline |
| Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104rule | EvolveImmune United | phase 1 | 11 running | CD3E, RAET1G, ULBP2 | NCIt |
Conditions their studies are in
- Amyotrophic Lateral Sclerosis, 1 program
- Arthritis, Rheumatoid, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Graft vs Host Disease, 1 program
- Kidney Diseases, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Lymphoma, B-Cell, 1 program
- Psoriasis, 1 program
- Urinary Bladder Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 4, 2027Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 · Novartis · phase 1 · NCT05397496
- Mar 28, 2028siplizumab · ITB-Med · phase 2 · NCT07508787
- Jan 29, 2029Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104 · EvolveImmune United · phase 1 · NCT07217171
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.